Rifapentine is an antibiotic agent used in the treatment of pulmonary tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells.
- Mechanism
- Curator reviewed
Rifapentine has shown higher bacteriostatic and bactericidal activities especially against intracellular bacteria growing in human monocyte-derived macrophages. Rifapentine inhibits DNA-dependent RNA polymerase in susceptible strains of M. tuberculosis. Rifapentine acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.
- Primary indication
- For the treatment of pulmonary tuberculosis.Curator reviewed · 2 structured indications
- Formula / weight
- C47H64N4O12 · 877.0307 g/mol (avg)
- First approval
- Canada, 2026 · United States, 2009
- Also known as
- Cyclopentylrifampicin · Rifapentin
- Code names
- ANTIBIOTIC DL-473IT · DL-473 · KTC-1 · MDL-473 · R-77-3
- Brand names
Resolves to
WDZCUPBHRAEYDL-GZAUEHORSA-NSMILESCO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Rifapentine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account